IL6 and COVID-19: Colchicine is one of the oldest anti-inflammatory therapies that is approved for treating and preventing acute gout attacks and familial Mediterranean fever.[16,17] Colchicine has been shown to interfere with the activation of the NLRP3 inflammasome, reducing IL-1 production, which in turn prevents IL-6 release and neutrophils and macrophages activation.[18–20] A few studies have evaluated the use of colchicine in hospitalized patients with COVID-19.